DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING METHOD FOR LEVODOPA, CARBIDOPA & ENTACAPONE IN TABLET DOSAGE FORM: BY RP- HPLC
DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING METHOD FOR LEVODOPA, CARBIDOPA & ENTACAPONE IN TABLET DOSAGE FORM: BY RP- HPLC
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
This research develops and validates a stability-indicating assay method for anti-Parkinson drugs in tablet form using reverse-phase HPLC. The objective is to create accurate, cost-effective analytical methods for API quantification through RP-HPLC and UV techniques. The approach involves standard and sample solution preparation, along with buffer formulation. Results show direct proportionality between analyte concentration and obtained areas, establishing linearity. The method demonstrates a suitable range, accurate recovery rates meeting acceptance criteria, precise results within limits, and robustness with no significant system suitability changes. This research provides reliable and economical analytical methods for assessing anti-parkinson drug quality and stability.